Raymond James Financial’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$19.5M Sell
105,806
-50,049
-32% -$10.9M 0.01% 1562
2026
Q2
$38.1M Buy
155,855
+8,089
+5% +$1.75M 0.01% 1092
2026
Q1
$24.3M Sell
147,766
-2,332
-2% -$403K 0.01% 1333
2025
Q4
$24.8M Sell
150,098
-8,591
-5% -$1.2M 0.01% 1290
2025
Q3
$19.3M Sell
158,689
-2,723
-2% -$307K 0.01% 1437
2025
Q2
$16.8M Buy
161,412
+6,337
+4% +$671K 0.01% 1494
2025
Q1
$18.1M Sell
155,075
-19,511
-11% -$2.22M 0.01% 1384
2024
Q4
$14.8M Buy
+174,586
New +$16.1M 0.01% 1532

Other funds holding AXSM

Raymond James Financial's AXSM Position: Q3 2026 in Review

Raymond James Financial reduced its Axsome Therapeutics (AXSM) stake by 32% in Q3 2026, selling an estimated $10.9M and leaving 105,806 shares worth $19.5M. The position accounts for 0.01% of the portfolio, ranked #1562.

Raymond James Financial first reported a position in AXSM in Q4 2024 and has held it in 8 quarters since. The position peaked at $38.1M in Q2 2026. 465 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Raymond James Financial held 105,806 shares of Axsome Therapeutics worth $19.5M as of Q3 2026.
  • Raymond James Financial sold 50,049 Axsome Therapeutics shares in Q3 2026, an estimated $10.9M.
  • Axsome Therapeutics made up 0.01% of Raymond James Financial's portfolio in Q3 2026, its #1562 holding.
  • Raymond James Financial first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • Raymond James Financial's Axsome Therapeutics position peaked at $38.1M in Q2 2026.
  • 465 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.